NCT05755035: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases |
|
|
| Recruiting | 2/3 | 75 | Europe, US, RoW | TAK-881, Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (rHuPH20)., HYQVIA, Immune Globulin Infusion (Human), 10% Solution with rHuPH20. | Takeda, Takeda Development Center Americas, Inc. | Primary Immunodeficiency Diseases (PID) | 02/26 | 09/26 | | |
RIGHT-HY, NCT06633289: Hypoallergenicity of a Hydrolyzed Rice Protein-based Formula in Infants and Young Children With Cow's Milk Protein Allergy |
|
|
| Not yet recruiting | N/A | 67 | Europe | Experimental formula, Control formula | Société des Produits Nestlé (SPN) | Cow's Milk Protein Allergy | 09/26 | 10/26 | | |
RIGHT-GO, NCT06633250: Effect of a Hydrolyzed Rice Protein-based Formula on Growth, Tolerance, and Health-related Quality of Life in Infants With Cow's Milk Protein Allergy. |
|
|
| Not yet recruiting | N/A | 104 | Europe | Test Formula, Control Formula | Société des Produits Nestlé (SPN) | Cow Milk Protein Allergy | 02/26 | 02/26 | | |
